Pendrina é um transportador de iodo na tiróide, codificada pelo gene PDS.Sabendo-se que o iodo é fundamental para a síntese de T3 e T4 foi objetivo avaliar o efeito do iodo na expressão gênica, atividade e promotor da pendrina. Foram utilizados ratos Wistar, que receberam injeção de salina ou 2mg de NaI. Após 30, 1, 24 e 48h as tiróides foram removidas para análise do mRNA e proteína, por PCR em Tempo Real e Western Blot. Ainda, utilizou-se celulas PCCl3, que foram tratadas ou não com 10-3M de NaI. Após 30, 1, 24 e 48h o RNA/proteína foram isolados.Determinou-se o efluxo pela medição do125I presente no meio de cultura. Para analisar a atividade do promotor, ele foi inserido no vetor pGL3-básico.Nossos resultados mostram que houve aumento do mRNA da pendrina em resposta ao iodo em todos os tempos estudados, porém não houve aumento da atividade promotora.A expressão da proteína pendrina, bem como taxa do efluxo de iodeto, aumentou nos tempos mais longos de tratamento.Esses dados apontam um importante papel de pendrina para o fenômeno de autoregulação da tiróide. / Pendrin is an iodide transporter in thyroid, encoded by the PDS gene. Since iodide is essential for the synthesis of T3 and T4, this study aimed to evaluate the iodine effect on pendrin gene expression and on the activity of its promoter. Male rats received an injection of saline or 2mg of NaI. After 30, 1, 24 and 48h the thyroids were removed for mRNA and protein analysis by Real Time PCR and Western Blot. Moreover, PCCl3 cells were treated or not with 10-3M NaI. After 30, 1, 24 and 48h the RNA/protein were isolated. The efflux was determined by measure of 125I in the culture medium. For the promoter analysis, it was inserted in pGL3-basic plasmid. The results indicated that the pendrin mRNA amount increased after iodide treatment. However, the promoter activity was unchanged. The protein expression and iodide efflux increased only after 24h of treatment. These data suggest an important role of pendrin for the autoregulation of the thyroid.

Pendrina é um transportador de iodo na tiróide, codificada pelo gene PDS.Sabendo-se que o iodo é fundamental para a síntese de T3 e T4 foi objetivo avaliar o efeito do iodo na expressão gênica, atividade e promotor da pendrina. Foram utilizados ratos Wistar, que receberam injeção de salina ou 2mg de NaI. Após 30, 1, 24 e 48h as tiróides foram removidas para análise do mRNA e proteína, por PCR em Tempo Real e Western Blot. Ainda, utilizou-se celulas PCCl3, que foram tratadas ou não com 10-3M de NaI. Após 30, 1, 24 e 48h o RNA/proteína foram isolados.Determinou-se o efluxo pela medição do125I presente no meio de cultura. Para analisar a atividade do promotor, ele foi inserido no vetor pGL3-básico.Nossos resultados mostram que houve aumento do mRNA da pendrina em resposta ao iodo em todos os tempos estudados, porém não houve aumento da atividade promotora.A expressão da proteína pendrina, bem como taxa do efluxo de iodeto, aumentou nos tempos mais longos de tratamento.Esses dados apontam um importante papel de pendrina para o fenômeno de autoregulação da tiróide. / Pendrin is an iodide transporter in thyroid, encoded by the PDS gene. Since iodide is essential for the synthesis of T3 and T4, this study aimed to evaluate the iodine effect on pendrin gene expression and on the activity of its promoter. Male rats received an injection of saline or 2mg of NaI. After 30, 1, 24 and 48h the thyroids were removed for mRNA and protein analysis by Real Time PCR and Western Blot. Moreover, PCCl3 cells were treated or not with 10-3M NaI. After 30, 1, 24 and 48h the RNA/protein were isolated. The efflux was determined by measure of 125I in the culture medium. For the promoter analysis, it was inserted in pGL3-basic plasmid. The results indicated that the pendrin mRNA amount increased after iodide treatment. However, the promoter activity was unchanged. The protein expression and iodide efflux increased only after 24h of treatment. These data suggest an important role of pendrin for the autoregulation of the thyroid.

A l’issue d’un accident nucléaire, les produits de fission de l’uranium tel les iodes radioactifs sont dispersés dans l’environnement. L’homme est susceptible d’être exposé à ces éléments majoritairement via l’inhalation d’air et/ ou l’ingestion d’aliments contaminés. L’iode 131 est connu pour être responsable de l’augmentation de l’incidence du cancer de la thyroïde. Une des contremesures pour prévenir cette pathologie est l’ingestion de dose unique de comprimés d’iodure de potassium (KI) à fin de saturer la glande thyroïde par de l’iode stable et d’éviter ainsi l’accumulation de l’iode radioactif. Les scénarios de rejets réitérés d’iodes radioactifs lors des deux accidents majeurs Tchernobyl et Fukushima ont mis en évidence les limites de cette mesure, des prises répétées de KI pour protéger dans le temps les populations s’avèrent nécessaires. Dans la littérature on dispose de peu de données clinique et préclinique sur la prise répétée d’iode stable, quant à son usage ça n’a pas été décrit. La doctrine iode ainsi que l’autorisation de mise sur le marché (AMM) du KI envisage seulement la prise unique à renouveler exceptionnellement chez la population adulte. L’iode est connu pour être un élément clé de la fonction thyroïdienne, on jouant un double rôle à la fois de substrat de régulateur de la thyroïde. Si sa présence est indispensable à la formation des hormones thyroïdienne, son excès exerce un effet inhibiteur transitoire de cette synthèse connu sous le nom de l’effet Wolff-Chaikoff. Les hormones thyroïdiennes jouent un rôle majeur dans le développement et la fonction de presque tous les organes du corps (cerveau, cœur, os...), la moindre variation de leurs niveau peut impacter l’homéostasie du corps. Ainsi, il est difficile d’appliquer la prise répétée du KI en absence connaissances biologiques et toxicologiques. Pour combler ses lacunes et proposer une solution de prophylaxie répétée en cas d’exposition réitérée, le programme de recherche français PRIODAC : PRophylaxie répétée par l’IODe stable en situation ACcidentelle (ANR/RSNR), dont fait partie cette thèse vise à exploiter les modalités d’administration répétées du KI chez toutes les tranches d’âge (in utero, adulte et âgé), et d’évaluer la toxicologie de la prise répétée de KI sur les grandes fonctions physiologiques de l’organisme. Trois modèles de rats Wistar ont fait l’objet de ce travail de thèse : le modèle de référence rat adulte (âgé de 3 mois), le modèle à risque, organisme en développement (exposé durant la gestation) et un autre modèle à risque le rat âgé (âgé de 12 mois), ces trois modèles ont reçus 8 prise consécutive de KI 1mg/kg/24h. Les effets biologiques de ce traitement pendant 8 jours ont été évalués à long-terme (30 jours post-prophylaxie). Concernant, le modèle de référence ont n’a pas observé d’impact néfaste à long-terme de la prise répétée du KI (Lebsir, Cohen et al. 2018; Lebsir, Manens et al. 2018) par contre sur les modèles à risque plusieurs effets à long-terme ont été mis en évidence. Chez la progéniture exposée in utero, la coordination motrice ainsi que l’expression de quelques gènes clés du cerveau ont été négativement modifiées par le traitement. Chez le rat âgé la biochimie clinique, l’expression de quelques gènes clés de la fonction cardiovasculaire ainsi que le système rénine-angiotensine-aldostérone ont été significativement impacté par le traitement. En conclusion, les résultats obtenus montrent l’innocuité sur le plan toxicologique du KI administré à 1mg/kg toutes les 24h pendant 8 jours chez le modèle adulte et la nocuité de ce schéma prophylactique chez les modèles à risque in utero et âgé. Ces résultats ont été communiquées à la pharmacie centrale des armées (producteur et détentrice de l’AMM) afin de servir de données d’entrée pour des études de bonne pratique de laboratoire notamment pour le modèle adulte et également, afin de contribuées à l’évolution de la doctrine de l’iode en terme de radioprotection. / Following nuclear accidents, uranium fission products such as radioactive iodines are released into the environment. Humans are likely to be exposed to these elements mainly through inhalation of air and / or ingestion of contaminated food. Iodine 131 is known to be responsible for increasing the incidence of thyroid cancer. One of the available countermeasures is the ingestion of a single dose of potassium iodide (KI) tablets to saturate the thyroid gland with stable iodine and thus prevent the uptake of the radioactive isotope.Repeated releases of radioactive iodine during the two major accidents Chernobyl and Fukushima have highlighted the weaknesses of this measure, repeated intake of KI maybe necessary. In the literature there is little clinical and preclinical data on the repeated intake of stable iodine, regarding its use it has not been described. The iodine doctrine as well as the Marketing Authorization (MA) of the KI considers only the single taking, to renew exceptionally in the adult population. Iodine is known to be a key component of thyroid function, playing a dual role as both a substrate and a regulator of the thyroid. If its presence is essential for the synthesis of thyroid hormones, its excess exerts a transient inhibitory effect on this synthesis known as the Wolff-Chaikoff effect. Thyroid hormones affect the development and function of almost all organs of the body (brain, heart, bone ...), the slightest variation in their level can impact the homeostasis of the body. Hence, the toughness of applying repeated KI intake in the absence of biological and toxicological data. To fill this gap and find a solution in the event of repeated exposure, the French research program PRIODAC: repeated potassium iodide prophylaxis in accidental situation (ANR / RSNR), of which this thesis is part, aims to define the modalities of repeated administration of KI in all age groups (in utero, adult and elderly), and evaluate the biological consequences on the the body’s major physiological functions. Three models of Wistar rats were used in this work: the reference model adult rat (3 months), the first sensitive model offspring (exposed during gestation) and another sensitive model the older rat (12 months ), these three models received 8 consecutive intake of KI 1mg / kg / 24h. And the effects were assessed at long-term (30 days post-prophylaxis). On the reference model, there was no long-term adverse impact of repeated KI intake (Lebsir, Cohen et al. 2018; Lebsir, Manens et al. 2018). On the other hand, sensitive models reveal several long-term effects; the offspring exhibited impaired motor coordination and variation of the expression of some key brain genes. And in the elderly rat urinary biochemistry, expression of some key genes of the cardiovascular function, as well as the renin-angiotensin-aldosterone system were significantly impacted by the treatment. In conclusion, the results obtained show the toxicological safety of KI administered at 1 mg / kg every 24 hours for 8 days in the adult model, and the harm of this prophylactic scheme in sensitive models in utero and elderly. These results were sent to the French central pharmacy of armies and will serve as input data for good laboratory practice studies that eventually will contribute to the evolution of the iodine doctrine and KI MA.